Skip to main content

Table 2 Treatment patterns

From: Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

  DMT-treated patients First Treatment Course
Oral Injectable Infusion
Duration of follow-up (mean, SD), mo 62.3 30.1 51.7 25.1 63.6 30.5 61.5 29.6
First DMT treatment course
Patients with first DMT course (n, %) 14,627 100 1583 100 12,796 100 248 100
Time to first DMT (mean, SD), mo 5.7 12.7 16.2 22.7 4.1 9.5 18.1 24.4
Time on first DMT (mean, SD), mo 28.1 25.9 21.0 17.5 29.0 26.7 27.2 25.4
First DMT end (n, %)
 Switch 2450 16.7 140 8.8 2287 17.9 23 9.3
 Discontinuation (≥60-day gap) 7447 50.9 741 46.8 6613 51.7 93 37.5
 End of follow-up period 4730 32.3 702 44.3 3896 30.4 132 53.2
Second DMT treatment course
Patients with second DMT (n, %) 7510 51.3 541 34.2 6898 53.9 71 28.6
Treatment gap (mean, SD), mo 5.1 9.3 4.6 6.4 5.2 9.6 5.9 7.7
Time on second DMT (mean, SD), mo 15.1 17.4 11.7 11.7 15.3 17.7 13.7 15.3
Second DMT end (n, %)
 Switcha 899 12.0 42 7.8 845 12.2 12 16.9
 Discontinuation (≥60-day gap)a 4172 55.6 277 51.2 3856 55.9 39 54.9
 End of follow-up perioda 2439 32.5 222 41.0 2197 31.8 20 28.2
Third DMT treatment course
Patients with third DMT (n, %) 3882 26.5 200 12.6 3645 28.5 37 14.9
Treatment gap (mean, SD), mo 5.0 7.2 4.7 6.0 5.0 7.3 3.8 5.4
Time on third DMT (mean, SD), mo 11.7 13.9 8.8 9.3 11.9 14.1 13.8 15.2
Third DMT end (n, %)
 Switchb 428 11.0 15 7.5 404 11.1 9 24.3
 Discontinuation (≥60-day gap)b 2248 57.9 100 50.0 2131 58.5 17 45.9
 End of follow-up periodb 1206 31.1 85 42.5 1110 30.5 11 29.7
  1. aPercentage calculated from number of patients with second-course DMT
  2. bPercentage calculated from number of patients with third-course DMT